IPCA Laboratories: Strong Q1 Performance Drives Rally

Stock up 5%+, with the recent move supported by strong Q1FY27 results and positive investor sentiment. Revenue grew 21% YoY, indicating healthy topline momentum. EBITDA surged 61% YoY, reflecting a significant improvement in operating performance. Net Profit increased 72% YoY, showing strong bottom-line growth. The stock has also touched a fresh all-time high of ₹1,945, highlighting strong market momentum. Brokerages have remained positive following the results, with some raising their target prices. Key Takeaway: IPCA Laboratories delivered a strong Q1FY27 performance, with robust growth across revenue, EBITDA and net profit. Sustaining this earnings momentum and improving profitability will remain key factors to watch. Disclaimer: This content is for educational and informational purposes only and should not be considered investment advice or a recommendation to buy or sell any security.